Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Carpenter Technology has reported and survived, trading at $395.71 after a week that exposed the gap between where the stock is and where analysts still think it should be.
The earnings event itself proved anticlimactic in price terms. The stock fell roughly 2% on the day of the July print, its most recent comparable, before recovering 5% over the following week. The October 6 result produced a gentler reaction: the stock added 0.9% on the day and is up just over 1% on the week. That modest bounce follows a brutal month, down nearly 17% from late September, which means CRS is still trading well below the $484 to $489 range where CEO Tony Thene sold more than 34,900 shares on August 25. Those sales were discretionary, with no 10b5-1 plan in place, and net insider disposals over the past 90 days total roughly 113,000 shares worth over $54 million. That context has not gone away simply because the print is now in the rearview mirror.
The positioning picture has loosened considerably since the pre-earnings setup. Short interest is stable near 3.2% of the free float, essentially flat on the week after a small overnight reduction. The borrow market is as easy as it gets: cost to borrow is 0.42%, and availability stands at around 4,400% of short interest, meaning there are vastly more shares available to lend than are currently borrowed. That looseness reflects no short-side conviction whatsoever. Options have shifted in the same direction. The put/call ratio has eased to 0.79, above its 20-day average of 0.65 but nowhere near the defensive readings above 1.0 seen through August and early September. The z-score of 0.86 puts the current PCR in unremarkable territory. Taken together, the market has moved from hedged caution to something closer to neutral, neither aggressive on the short side nor loading up on downside protection.
The Street's math remains hard to reconcile with the current price. The consensus mean target is $612, implying roughly 55% upside from $395. Wells Fargo was the most recent mover, cutting its target to $430 from $540 at the end of September while holding an Equal-Weight rating, a clear signal that at least one bellwether firm sees limited near-term recovery. The bull case rests on tightening nickel-based superalloy supply, strong Specialty Alloys Operations margins, and an EBITDA of roughly $223 million for the third quarter that beat estimates. The bear case points to cyclical aerospace demand, raw-material cost sensitivity, and a narrow customer base. EV/EBITDA is running near 17.4x with price-to-book at 5.9x, both effectively flat on the week but well off the highs implied by the pre-correction price. The 90-day EPS momentum factor scores in the 93rd percentile, suggesting estimate revisions have been running strongly positive even as the stock has been sold down.
On the institutional side, the most notable recent move is JP Morgan Asset Management adding roughly 691,000 shares as of September 30, making it a top-15 holder. BlackRock lifted its reported stake to above 10% in a recent 13G amendment. At the other end, Lone Pine Capital trimmed by around 855,000 shares and SurgoCap Partners cut by roughly 510,000, both as of June 30 data, meaning the exits preceded the sharpest leg of the sell-off. No 13D activist is on the register; all major holders have filed passive 13G schedules, and the standard caveat applies: positions reflect the most recent disclosure around the 5% threshold and may have changed since.
The next print is scheduled for October 22, fifteen days away. The debate heading into it is less about whether aerospace demand is accelerating and more about whether the Street's target corridor, still clustered between $430 and $700 across the analysts who have moved recently, will begin to compress toward the stock's actual trading level, or whether CRS closes the gap from below.
See the live data behind this article on ORTEX.
Open CRS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
